Celgene (CELG) Affirms $600M Acquisition of EngMab - Bloomberg, Citing Statement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Stocks and yen struggle as tech troubles weigh
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen hits fresh 34-year lows against dollar ahead of BOJ meeting
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Celgene (CELG) Said to Acquire Swiss Biotech in $600M Deal
September 30, 2016 11:06 AM EDTCelgene (Nasdaq: CELG) said to acquire Swiss biotech EngMab in a deal valued at $600 million, according to Endpoints News. The site said... More
Celgene (CELG) Acquires Swiss Biotech EngMab for $600M - EndPoint News
September 30, 2016 11:06 AM EDTCelgene (NASDAQ: CELG) has agreed to acquire Swiss biotech EngMab for $600 million, EndPoint news reported.
... MoreCelgene (CELG): Clinical CELMoD Data Creates LT Optionality - BMO
September 30, 2016 7:46 AM EDTBMO Capital analyst, Ian Somaiya, reiterated his Outperform rating on Celgene (NASDAQ: CELG) after the company unveiled clinical data from its CELMoD pipeline, showcasing its expertise in protein homeostasis.
The near-term impact on CELG shares is expected to be limited but the pipeline... More
